Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Cytokinetics (CYTK – Research Report) and ...

Recent label updates for Bristol Myers’ Camzyos should read positively for obstructive hypertrophic cardiomyopathy patients and physicians, as they could lead to greater categor ...

Insiders have been trading these 5 stocks: (($CYTK)), (($BJ)), (($GTE)), (($PBF)) and (($IMVT)). Here is a breakdown of their recent trades and ...

We recently published a list of the 10 Best High Short Interest Stocks to Buy Now. In this article, we are going to take a ...

The stock options and RSUs were granted as material inducements to employment in accordance with Nasdaq Listing Rule 5635 (c) ...

BMS could soon face competition in the HCM space as Cytokinetics awaits a marketing application decision from the FDA for ...

Bristol Myers Squibb’s examination into whether its heart med Camzyos can spark improvements in patients with non-obstructive ...

Camzyos’ failure in a form of hypertrophic cardiomyopathy dampened its commercial outlook and spurred debate as to whether ...

J&J also raised its full-year revenue guidance to include sales of the psychiatric drug Caplyta, which the company got from ...

Bristol Myers Squibb stock skidded late Monday, tugging Cytokinetics lower, after Bristol's drug, Camzyos, failed in a heart disease study.

Aficamten, a cardiac myosin inhibitor (CMI), is the cornerstone of Cytokinetics' near-term prospects. The drug has shown promising results in clinical trials, demonstrating significant gradient ...

Heart failure with preserved ejection fraction (HFpEF) is a disease in which the left ventricle (LV) of the heart shows impaired relaxation during cardiac diastole, often accompanied by structural and ...